Results 71 to 80 of about 376,110 (130)

CytoSorb®-Anwendung : Assoziation mit klinischem Outcome in der Herzchirurgie

Das Auftreten eines systemisch inflammatorischen Response-Syndroms (SIRS) im Rahmen eines herzchirurgischen Eingriffes steht bei Persistenz im Zusammenhang mit einer erhöhten Morbidität und Mortalität.
Biehler, Natalie
core   +1 more source

Effective Apixaban removal using hemoadsorption during emergent open-heart surgery: a case report and narrative literature review

Journal of Cardiothoracic Surgery
Background The management of hemostasis in patients medicated with apixaban (Eliquis) undergoing emergency cardiac surgery is exceedingly difficult. The body’s natural elimination pathways for apixaban prove ineffective in emergency situations, and the ...
Vitor Mendes, Jaid Mamode, Jalal Jolou, Mourad Malki, Christoph Ellenberger, Mustafa Cikirikcioglu, Christoph Huber   +6 more
doaj   +1 more source

Extracorporeal Hemadsorption versus Glucocorticoids during Cardiopulmonary Bypass: A Prospective, Randomized, Controlled Trial

Cardiovascular Therapeutics, 2020
Extracorporeal hemadsorption may reduce inflammatory reaction in cardiopulmonary bypass (CPB) surgery. Glucocorticoids have been used during open-heart surgery for alleviation of systemic inflammation after CPB.
Gordana Taleska Stupica, Maja Sostaric, Marija Bozhinovska, Lea Rupert, Zoran Bosnic, Ales Jerin, Alojz Ihan, Tomislav Klokocovnik, Matej Podbregar   +8 more
doaj   +1 more source

CytoResc – “CytoSorb” Rescue for critically ill patients undergoing the COVID-19 Cytokine Storm: A structured summary of a study protocol for a randomized controlled trial

Trials, 2020
Objectives Approximately 8 - 10 % of COVID-19 patients present with a serious clinical course and need for hospitalization, 8% of hospitalized patients need ICU-treatment. Currently, no causal therapy is available and treatment is purely supportive.
Helena Stockmann, Theresa Keller, Stefan Büttner, Achim Jörres, Detlef Kindgen-Milles, Julius Valentin Kunz, Josef Leebmann, Claudia Spies, Karl Träger, Sascha Treskatsch, Alexander Uhrig, Carsten Willam, Philipp Enghard, Torsten Slowinski, for the CytoResc Trial Investigators   +14 more
doaj   +1 more source

Severe Vasoplegic Syndrome Treated with Angiotensin II and Hemoadsorption Therapy after Cardiac Surgery

Catheterization and Cardiovascular Interventions, Volume 106, Issue 3, Page 1740-1745, September 1, 2025.
ABSTRACT Vasoplegic syndrome (VS) is a common complication after cardiac surgery with cardiopulmonary bypass (CPB). The main pathophysiology mechanism of VS includes a systemic inflammatory response syndrome due to surgical trauma, release of pro‐inflammatory mediators caused by blood contact with foreign surfaces of heart‐lung machine (pump and tubing)
Matteo Lucchelli, Davide Tommaso Andreis, Mattia Gomarasca, Giovanni Mistraletti   +3 more
wiley   +1 more source

Cytosorb® haemoadsorption: a potential game changer for patients needing myocardial surgical revascularisation

, 2022
Cytosorb, an extracorporeal blood purification system, utilises the principles of haemoadsorption to remove low molecular weight substances from the blood, including multiple cytokines such as interleukin (IL)-1b, IL-6, IL-8, and tumour necrosis factor-α,
Raja, Shahzad G., de Waal, Eric E.C., Marczin, Nandor, Umakumar, Kabeer, Stock, Ulrich A., Ng Yin Ling, Clarissa, Moss, Louise   +6 more
core  

Can the cytokine adsorber CytoSorb® help to mitigate cytokine storm and reduce mortality in critically ill patients? A propensity score matching analysis

Annals of Intensive Care, 2021
Background A cytokine storm is life threatening for critically ill patients and is mainly caused by sepsis or severe trauma. In combination with supportive therapy, the cytokine adsorber Cytosorb® (CS) is increasingly used for the treatment of cytokine ...
Christina Scharf, Ines Schroeder, Michael Paal, Martin Winkels, Michael Irlbeck, Michael Zoller, Uwe Liebchen   +6 more
doaj   +1 more source

Effects of empagliflozin on uric acid levels during acute heart failure recompensation: A sub‐analysis of the EMPAG‐HF trial (Effects of Empagliflozin on Diuresis and Renal Function in Patients with Acute Decompensated Heart Failure)

European Journal of Heart Failure, Volume 27, Issue 8, Page 1472-1478, August 2025.
Effects of empagliflozin on uric acid levels during acute heart failure recompensation. Abstract Background Sodium–glucose cotransporter 2 inhibitors improve prognosis in chronic heart failure as part of currently recommended therapeutic strategies.
Jurgen Bogoviku, Tien Dung Nguyen, Julian Georg Westphal, Franz Haertel, Pawel Aftanski, Sven Möbius‐Winkler, Martin Busch, P. Christian Schulze   +7 more
wiley   +1 more source

Additional file 1 of Extracorporeal adsorption of protective and toxic bile acids and bilirubin in patients with cholestatic liver dysfunction: a prospective study

, 2023
Additional file 1. Table S1a: Total bilirubin concentration (mg/dL) pre- and post-Cytosorb® at different timepoints. Table S1b: Conjugated bilirubin concentration (mg/dL) pre- and post-Cytosorb® at different timepoints.
Katharina Habler (1409287), Clara Isabell Brozat (17369240), Uwe Liebchen (9677184), Michael Paal (3024075), Antonia Greimel (17369231), Michael Zoller (4530031), Christina Scharf (4530028), Nils Maciuga (17369237), Michael Vogeser (364534), Caroline Gräfe (17369234), Felix L. Happich (17369243), Sandra Frank (10029431)   +11 more
core   +1 more source

Current and novel biomarkers in cardiogenic shock

European Journal of Heart Failure, Volume 27, Issue 6, Page 1106-1125, June 2025.
A summary of current and novel biomarkers and their potential stages of release in cardiogenic shock. The diagram illustrates the proposed release of the biomarkers during the different stages of cardiogenic shock: progression from cardiac dysfunction/stress, through to inflammation and end‐organ dysfunction.
Victor Galusko, Florian A. Wenzl, Christophe Vandenbriele, Vasileios Panoulas, Thomas F. Lüscher, Diana A. Gorog   +5 more
wiley   +1 more source